<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584010</url>
  </required_header>
  <id_info>
    <org_study_id>All-M-42361-01-08-14</org_study_id>
    <nct_id>NCT02584010</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Two Silicon-based Products to Treat Scars</brief_title>
  <acronym>Kelofin</acronym>
  <official_title>Comparative, Open, Randomized Trial Between Two Silicon-based Products to Treat Postoperative Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if a silicon-based gel and a silicon-based aerosol are effective&#xD;
      in the treatment of postoperative scars.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Improve the final aspect of scars, have been a challenge for medicine. Silicon based products&#xD;
      have been used in various ways to prevent hypertrophic scars and keloids since 1980. A great&#xD;
      percentage of studies shows that silicon-based products improves the aspect of scars in&#xD;
      different pathologies. The main objective of this trial is to evaluate the efficacy, using&#xD;
      the Vancouver scale, of two silicon-based products (Kelofin gel and Kelofin aerosol) after&#xD;
      180 days.&#xD;
&#xD;
      300 participants that meet all the inclusion criteria and are not classified in any of the&#xD;
      exclusion criteria will be randomly allocated to one of thre treatment groups( Kelofin Gel,&#xD;
      Kelofin Aerosol and no treatment) of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of scars clinical improvement</measure>
    <time_frame>180 days</time_frame>
    <description>The scars will be evaluated by the Vancouver scale since the baseline visit until 180 days after the end of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of scars color improvement</measure>
    <time_frame>180 days</time_frame>
    <description>The scars will be evaluated by the equipment Mexameter (Courage+Khazaka®) since the baseline visit until 180 days after the end of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of scars measurement improvement</measure>
    <time_frame>180 days</time_frame>
    <description>The scars will be evaluated by the equipment Optical 3D Skin Measuring Device PRIMOS Compact 5.075, since the baseline visit until 180 days after the end of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants satisfaction regarding the treatment</measure>
    <time_frame>180 days</time_frame>
    <description>Assess the satisfaction of participants regarding the treatment on each visit using a questionnaire on improving the healing process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>180 days</time_frame>
    <description>Adverse events will be evaluated since the baseline visit until 180 days after the end of the treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>Kelofin Aerosol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silicon-based Aerosol that will be applied over the postoperative scar two times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kelofin Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silicon-based Gel that will be applied over the postoperative scar two times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will not receive any intervention as a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Silicon-based aerosol</intervention_name>
    <description>Apply twice a day over the postoperative scar</description>
    <arm_group_label>Kelofin Aerosol</arm_group_label>
    <other_name>Kelofin Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Silicon-based gel</intervention_name>
    <description>Apply twice a day over the postoperative scar</description>
    <arm_group_label>Kelofin Gel</arm_group_label>
    <other_name>Kelofin Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fitzpatrick skin phototype I, II, III or IV&#xD;
&#xD;
          -  Participant that has a recent surgical scar on remodeling phase (14 ± 7 days after&#xD;
             surgery) from the following: breast plastic with inframammary incision (fold beneath&#xD;
             the breast) or abdominoplasty, cesarean section, hysterectomy (removal of the uterus),&#xD;
             oophorectomy (removal of ovaries), oophoroplasty (removal of nodules, cysts, etc. of&#xD;
             the ovaries), salpingectomy (removal of the fallopian tubes), tubal ligation,&#xD;
             exploratory laparotomy and ectopic pregnancy (pregnancy outside the uterus)&#xD;
             (Pfannenstiel access road - transverse incision , below the navel and approximately&#xD;
             one finger above the symphysis pubis).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin Pathology in the product application area;&#xD;
&#xD;
          -  Diabetes;&#xD;
&#xD;
          -  Immune impairment;&#xD;
&#xD;
          -  Use of systemic corticosteroids or immunosuppressants;&#xD;
&#xD;
          -  Skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis;&#xD;
&#xD;
          -  Background reaction to silicon-based products;&#xD;
&#xD;
          -  Other illnesses or medications that may interfere directly in the study or endanger&#xD;
             the health of the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative scars</keyword>
  <keyword>Cicatrix</keyword>
  <keyword>Cicatrization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

